Enzalutamide With or Without Abiraterone & Prednisone in Treating Patients

Status Active, not recruiting

Clinical Trial Summary

This randomized phase III trial studies enzalutamide to see how well it works compared to enzalutamide, abiraterone, and prednisone in treating patients with castration-resistant metastatic prostate cancer. Androgens can cause the growth of prostate cancer cells. Drugs, such as enzalutamide, abiraterone acetate, and prednisone, may lessen the amount of androgens made by the body.

Clinical Trial Description

Patients are randomized to one of two treatment groups: enzalutamide or enzalutamide, abiraterone and prednisone. Treatment will continue until disease progression or unacceptable toxicity. Patients are followed for clinical outcomes for a maximum of 5 years post study treatment. The primary and secondary objectives are described below. 1. Primary Objective: To compare the overall survival of patients with progressive metastatic castration-resistant prostate cancer (CRPC) treated with either enzalutamide only or enzalutamide with abiraterone and prednisone 2. Secondary Objectives: - To assess the grade 3 or higher toxicity profile and compare safety by treatment arm. - To assess and compare post-treatment prostate-specific antigen (PSA) declines by treatment arm. - To compare radiographic progression free survival defined by Prostate Cancer Working Group 2 (PCWG2), and objective response rate, by treatment arm. - To test for radiographic progression free survival (rPFS) treatment interaction in predicting overall survival. - To assess pre- and post-treatment measures of tumor burden and bone activity using sodium fluoride (NaF) positron emission tomography (PET)/computed tomography (CT) and technetium (Tc) methylene diphosphonate (MDP) bone scintigraphy and correlate these measures with overall survival. - To develop and validate prognostic and predictive models of overall survival that include baseline clinical and molecular markers. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01949337
Study type	Interventional
Source	Alliance for Clinical Trials in Oncology
Contact
Status	Active, not recruiting
Phase	Phase 3
Start date	January 22, 2014
Completion date	August 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02217709` - Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer	Phase 2
Completed	`NCT03077659` - Trial of NanoPac® Focal Therapy in Subjects With Prostate Cancer	Phase 2
Active, not recruiting	`NCT03624660` - Dose-Escalated Proton Radiation Therapy for High-Risk Prostate Cancer	N/A
Completed	`NCT01054079` - Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer	Phase 2
Terminated	`NCT00512668` - Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer	Phase 1
Completed	`NCT00087139` - Ixabepilone in Treating Patients With Metastatic Prostate Cancer	Phase 2
Completed	`NCT00182052` - Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer	Phase 3
Active, not recruiting	`NCT03511196` - Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer	Early Phase 1
Active, not recruiting	`NCT01655836` - High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer	Phase 1
Terminated	`NCT03535675` - Muscadine Plus (MPX) In Men With Prostate Cancer	Phase 3
Terminated	`NCT01866423` - Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer	Phase 2
Completed	`NCT02234921` - Pilot Study of DRibble Vaccine for Prostate Cancer Patients	Phase 1
Completed	`NCT01468532` - Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer	Phase 1/Phase 2
Active, not recruiting	`NCT03686683` - Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer	Phase 3
Active, not recruiting	`NCT03689699` - Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)	Phase 1/Phase 2
Recruiting	`NCT04694924` - Prospective Prostate Cancer and Patient-reported Outcomes Registry
Active, not recruiting	`NCT04909294` - Evaluation of the Efficacy and the Safety of a Stereotaxic Prostatic Radiotherapy Delivered With Linac MRI, in Patients With Prostate Adenocarcinoma	N/A
Completed	`NCT02225925` - Intraoperative Dosimetry for Prostate Brachytherapy Using Fluoroscopy and Ultrasound	N/A
Completed	`NCT01949519` - Docetaxel and Lycopene in Metastatic Prostate Cancer	Phase 1
Completed	`NCT01433913` - Metformin Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms